Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing

被引:1
|
作者
Salama, Engie [1 ]
Lam, Stepfanie [1 ]
Gonsalves, Wilson, I [2 ]
Tzachanis, Dimitrios [3 ]
Momper, Jeremiah D. [1 ]
Saunders, Ila M. [1 ]
机构
[1] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, 9500 Gilman Dr,MC 0657, La Jolla, CA 92093 USA
[2] Mayo Clin, Div Hematol, Rochester, MN USA
[3] Univ Calif San Diego Hlth, Moores Canc Ctr, La Jolla, CA USA
关键词
multiple myeloma; pharmacokinetics; lenalidomide; renal impairment; CREATININE CLEARANCE; PHARMACOKINETICS; RECOMMENDATIONS;
D O I
10.1177/10600280221087218
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Lenalidomide is an immunomodulatory drug used to treat multiple myeloma that requires renal dosing adjustment based on Cockcroft-Gault (CG). Various equations to estimate kidney function exist and pose a potential issue with lenalidomide dosing. Objective The objective of this analysis was to evaluate the impact of estimating kidney function in newly diagnosed multiple myeloma patients with CG, Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and their potential impact on lenalidomide dosing. Methods Data from 1121 multiple myeloma patients at the time of diagnosis acquired from the Mayo Clinic were used to calculate creatinine clearance (CrCl) using Cockcroft-Gault with actual body weight (CG(ABW)), ideal body weight (CG(IBW)), or adjusted body weight (CG(AdjBW)); MDRD; and CKD-EPI for each subject. Discordances in dosing were then analyzed, and lenalidomide exposure was calculated for each subject to assess impact on pharmacokinetics of lenalidomide for patients who received discordant doses. Results Overall, approximately 16% of patients received a discordant dose when using MDRD or CKD-EPI instead of CG(ABW). The most common dose discordance was the decrease of a full dose of lenalidomide 25 mg when using CG(ABW) down to 10 mg and when using MDRD or CKD-EPI with 53.8% to 55.6% of all discordances in this category. When assessing different body weights, the most common discordance was a decrease from 25 to 10 mg when using CG(IBW) instead of CG(ABW); the same trend was observed when using CG(AdjBW) instead as well. Patients were also at risk of over- or underexposure based on area under the concentration versus time curve (AUC) for discordant dosing. Conclusion and Relevance A significant proportion of patients are at risk of under- or overdose of lenalidomide if CKD-EPI or MDRD are used instead of CG(ABW). Physicians should use CG(ABW) when estimating renal function to dose lenalidomide.
引用
收藏
页码:29 / 35
页数:7
相关论文
共 50 条
  • [21] Lenalidomide in multiple myeloma
    Kim, Young
    Schmidt-Wolf, Ingo G. H.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (05) : 491 - 497
  • [22] REVISED LENALIDOMIDE DOSING FOR MYELOMA PATIENTS RECEIVING DIALYSIS: SAFETY AND SUCCESSFUL
    Merchionne, F.
    Guaragna, G.
    Rinaldi, E.
    Coppi, M. R.
    Brocca, M. C.
    Solfrizzi, M. P.
    Melpignano, A.
    HAEMATOLOGICA, 2017, 102 : 165 - 166
  • [23] Decreased neutrophil function in newly diagnosed multiple myeloma patients is restored with lenalidomide therapy
    Askman, Sandra
    Westerlund, Julia
    Pettersson, Asa
    Hellmark, Thomas
    Johansson, Asa
    Wichert, Stina
    Hansson, Markus
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (01) : 72 - 81
  • [24] Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant
    Shockley, Abigail
    Davis, James A.
    Gaffney, Kelly J.
    Smith, Deidra
    Weeda, Erin
    Hashmi, Hamza
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (07) : 1613 - 1616
  • [25] Estimation of kidney function to adjust drug dosing
    Rojas, Luis E.
    Juan, Pablo Huidobro E.
    REVISTA MEDICA DE CHILE, 2022, 150 (07) : 924 - 929
  • [26] How lenalidomide is changing the treatment of patients with multiple myeloma
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Niesvizky, Ruben
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 88 : S23 - S35
  • [27] THOMBOPROPHYLAXIS IN MULTIPLE MYELOMA PATIENTS TREATED WITH LENALIDOMIDE OR THALIDOMIDE
    Palmaro, A.
    Despas, F.
    Lapeyre-Mestre, M.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E65 - E65
  • [28] LENALIDOMIDE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Okada, K.
    Okamoto, Y.
    Tsukamoto, T.
    Sugiura, H.
    Matsui, H.
    Ueda, T.
    Jo, T.
    Onishi, T.
    Kunitomi, A.
    Ueda, Y.
    ANNALS OF ONCOLOGY, 2013, 24
  • [29] Lenalidomide maintenance in young and elderly patients with Multiple Myeloma
    Fouquet, Guillemette
    Gay, Julie
    Demarquette, Helene
    Bonnet, Sarah
    Leleu, Xavier
    HEMATOLOGIE, 2012, 18 (03): : 170 - 174
  • [30] Lenalidomide and stem cell collection in patients with multiple myeloma
    Cook, R. J.
    Vogl, D.
    Mangan, P. A.
    Cunningham, K.
    Luger, S.
    Porter, D. L.
    Tsai, D. E.
    Raguza-Lopez, M.
    Wiley, K.
    Masters, K.
    Stadtmauer, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)